These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 36055212)

  • 1. Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies.
    Harlow CE; Gandawijaya J; Bamford RA; Martin ER; Wood AR; van der Most PJ; Tanaka T; Leonard HL; Etheridge AS; Innocenti F; Beaumont RN; Tyrrell J; Nalls MA; Simonsick EM; Garimella PS; Shiroma EJ; Verweij N; van der Meer P; Gansevoort RT; Snieder H; Gallins PJ; Jima DD; Wright F; Zhou YH; Ferrucci L; Bandinelli S; Hernandez DG; van der Harst P; Patel VV; Waterworth DM; Chu AY; Oguro-Ando A; Frayling TM
    Am J Hum Genet; 2022 Sep; 109(9):1638-1652. PubMed ID: 36055212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction.
    Larsson SC; Burgess S; Michaëlsson K
    JAMA; 2017 Jul; 318(4):371-380. PubMed ID: 28742912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Vitamin E Levels and Risk of Coronary Artery Disease and Myocardial Infarction: A Mendelian Randomization Study.
    Wang T; Xu L
    Nutrients; 2019 Sep; 11(9):. PubMed ID: 31505768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.
    Harlow CE; Patel VV; Waterworth DM; Wood AR; Beaumont RN; Ruth KS; Tyrrell J; Oguro-Ando A; Chu AY; Frayling TM
    Hum Mol Genet; 2023 Jan; 32(3):496-505. PubMed ID: 36048866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Liability to Depression and Risk of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes.
    Lu Y; Wang Z; Georgakis MK; Lin H; Zheng L
    J Am Heart Assoc; 2021 Jan; 10(1):e017986. PubMed ID: 33372528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study.
    Miao L; Deng GX; Yin RX; Nie RJ; Yang S; Wang Y; Li H
    Eur J Prev Cardiol; 2021 Apr; 28(2):227–234. PubMed ID: 33838042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of bi-directional causal association between depression and cardiovascular diseases: a Mendelian randomization study.
    Li GH; Cheung CL; Chung AK; Cheung BM; Wong IC; Fok MLY; Au PC; Sham PC
    Psychol Med; 2022 Jul; 52(9):1765-1776. PubMed ID: 33032663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.
    Lanktree MB; Thériault S; Walsh M; Paré G
    Am J Kidney Dis; 2018 Feb; 71(2):166-172. PubMed ID: 28754456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causal effect of Lipoprotein-associated phospholipase A2 activity on coronary artery disease and myocardial Infarction: A Two-Sample Mendelian Randomization study.
    Sun L; Zhu Z; Shi M; Jia Y; Yang P; Wang Y; Liu F; Zhang Y
    Clin Chim Acta; 2021 Dec; 523():491-496. PubMed ID: 34740601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M; Tanaka T; Nangaku M
    Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis.
    Wu M; Zang C; Ma F; Chen B; Liu J; Xu Z
    Clin Exp Nephrol; 2022 Nov; 26(11):1043-1054. PubMed ID: 36006596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mendelian Randomization Studies Do Not Support a Role for Vitamin D in Coronary Artery Disease.
    Manousaki D; Mokry LE; Ross S; Goltzman D; Richards JB
    Circ Cardiovasc Genet; 2016 Aug; 9(4):349-56. PubMed ID: 27418593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiology and pathophysiology of renal erythropoietin-producing cells.
    Shih HM; Wu CJ; Lin SL
    J Formos Med Assoc; 2018 Nov; 117(11):955-963. PubMed ID: 29655605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.